title: Suppression of ventricular arrhythmias during ischemia-reperfusion by agents inhibiting Ins(1,4,5)P3 release.
abstract: BACKGROUND
  Reperfusion following myocardial ischemia causes a rapid and transient release of inositol (1,4,5)triphosphate [Ins(1,4,5)P3]. The aim of this study was to test whether this increased Ins(1,4,5)P3 release was important for the development of ventricular arrhythmias and whether agents that inhibit this signal transduction pathway, such as aminoglycoside antibiotics, suppress arrhythmias.
  
  
  RESULTS
  In perfused rat hearts, ventricular tachycardia (VT), ventricular fibrillation (VF), and accumulation of Ins(1,4,5)P3 were measured during early reperfusion. A number of different compounds, including neomycin, gentamicin, streptomycin, spermine, reserpine, and prazosin, were effective in inhibiting the reperfusion-induced Ins(1,4,5)P3 release and the onset of VT and VF in parallel. A strong correlation existed between Ins(1,4,5)P3 content, measured at 2 minutes of reperfusion, and the incidence of reperfusion VT and VF. In addition, intravenous gentamicin suppressed the onset of arrhythmias under ischemic and reperfusion conditions in vivo.
  
  
  CONCLUSIONS
  Our results are consistent with the view that Ins(1,4,5)P3 release plays a pivotal role in mediating arrhythmias during early reperfusion. Agents inhibiting Ins(1,4,5)P3 release are antiarrhythmic and may have potential use clinically.
authors.affiliation: Alfred and Baker Medical Unit, Alfred Hospital and Baker Medical Research Institute, Melbourne, Australia.
authors.forename: X J
authors.initials: XJ
authors.lastname: Du
authors.forename: K E
authors.initials: KE
authors.lastname: Anderson
authors.forename: A
authors.initials: A
authors.lastname: Jacobsen
authors.forename: E A
authors.initials: EA
authors.lastname: Woodcock
authors.forename: A M
authors.initials: AM
authors.lastname: Dart
mesh_terms: D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D005839:Gentamicins / Q000494:pharmacology; D015544:Inositol 1,4,5-Trisphosphate / Q000037:antagonists & inhibitors* / Q000502:physiology; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000150:complications* / Q000503:physiopathology; D010477:Perfusion; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012110:Reserpine / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D013096:Spermine / Q000494:pharmacology; D019311:Staurosporine; D017180:Tachycardia, Ventricular / Q000209:etiology / Q000517:prevention & control*; D014693:Ventricular Fibrillation / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000470:Alkaloids; D000889:Anti-Arrhythmia Agents; D000900:Anti-Bacterial Agents; D005839:Gentamicins; D013096:Spermine; D015544:Inositol 1,4,5-Trisphosphate; D012110:Reserpine; D019311:Staurosporine; D011224:Prazosin